Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1% [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street's revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per share was 1.9% below analysts' consensus estimates. Is now the time to buy Amphastar Pharmaceuticals? Find out in our full research report Amphastar Pharmaceuticals (AMPH) Q4 CY2024 Highlights: Revenue: $186.5 million vs analyst estimates of $189.2 million (4.7% year-on-year growth, 1.4% miss) Adjusted EPS: $0.92 vs analyst expectations of $0.94 (1.9% miss) Operating Margin: 24.2%, down from 30.3% in the same quarter last year Market Capitalization: $1.50 billion Company Overview Founded in 1996, Amphastar Pharmaceuticals (NASDAQ:AMPH) develops, manufactures, and markets injectable and inhalation products, focusing on critical care, emergency, and chronic conditions. Generic Pharmaceuticals The generic pharmaceutical industry operates on a volume-driven, low-cost bus
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Will FDA Approval of an In-House Teriparatide Pen Reshape Amphastar Pharmaceuticals' (AMPH) Narrative? [Yahoo! Finance]Yahoo! Finance
- Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile [Seeking Alpha]Seeking Alpha
- 2 Russell 2000 Stocks for Long-Term Investors and 1 Facing Challenges [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by analysts at Barclays PLC to a "hold" rating.MarketBeat
- Amphastar Pharmaceuticals (NASDAQ:AMPH) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $30.00 price target on the stock.MarketBeat
AMPH
Earnings
- 11/6/25 - Beat
AMPH
Sec Filings
- 12/18/25 - Form 4
- 12/15/25 - Form 4
- 12/11/25 - Form 144
- AMPH's page on the SEC website